| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO | /s/ David Pauling as attorney-in-fact for Hans-Peter Gerber | 22 Sep 2025 | 0001992979 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | STRO | Common Stock | Options Exercise | $0 | +37,500 | +122% | $0.000000 | 68,249 | 18 Sep 2025 | Direct | |
| transaction | STRO | Common Stock | Tax liability | $12,075 | -13,417 | -20% | $0.9000 | 54,832 | 18 Sep 2025 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | STRO | Restricted Stock Units (RSUs) | Options Exercise | $0 | -37,500 | -33% | $0.000000 | 75,000 | 18 Sep 2025 | Common Stock | 37,500 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| F2 | Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. |
| F3 | The RSU award vests annually as to 1/4th of the total award beginning on September 18, 2024, subject to the reporting person's continued service to the Issuer on each vesting date. |